Compare
Milestone Pharmaceuticals Inc. vs Rezolute, Inc. vs Avalo Therapeutics, Inc. vs Aardvark Therapeutics, Inc.
| Latest fiscal year | Milestone Pharmaceuticals Inc. MIST | Rezolute, Inc. RZLT | Avalo Therapeutics, Inc. AVTX | Aardvark Therapeutics, Inc. AARD |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-06-30 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $59.0K | $0 |
| Revenue growth (YoY) | n/a | n/a | -86.6% | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/m | n/a |
| Net margin | n/a | n/a | n/m | n/a |
| Net income | -$63.06M | -$77.59M | -$78.26M | -$57.59M |
| EPS (Diluted) | -$0.75 | -$0.75 | -$5.84 | -$2.93 |
| Operating cash flow | -$49.04M | -$64.64M | -$51.46M | -$54.17M |
| Free cash flow | -$49.34M | n/a | n/a | -$54.27M |
| Cash & equivalents | $73.05M | $10.62M | $15.86M | $47.05M |
| Total assets | $113.56M | $112.85M | $116.46M | $117.18M |
| Total liabilities | $71.79M | $12.16M | $33.41M | $10.55M |
| Shareholders' equity | $41.77M | $100.69M | $83.05M | $106.63M |
| Return on year-end equity | -151.0% | -77.1% | -94.2% | -54.0% |
| Shares outstanding | 106.24M | 96.41M | 18.51M | 21.82M |
Revenue, most recent five fiscal years
| Fiscal year | Milestone Pharmaceuticals Inc. | Rezolute, Inc. | Avalo Therapeutics, Inc. | Aardvark Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | n/a | $59.0K Ended 2025-12-31 | $0 Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | $441.0K Ended 2024-12-31 | n/a |
| 2 years earlier | n/a | n/a | $1.92M Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | n/a | $18.05M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | n/a | $5.40M Ended 2021-12-31 | n/a |